Abstract

529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Abstract CT254: A first-in-human phase 1 study of the safety and pharmacokinetics of XB002 in patients with inoperable locally advanced or metastatic solid tumors
Melissa Johnson ... Haeseong Park
American Journal of Cancer | VOL. 82
Melissa Johnson, et. al.Melissa Johnson ... Haeseong Park
15 Jun 2022
Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study.
Kyaw Z Thein ... Lacey Mcquinn
Journal of Immunotherapy and Precision Oncology | VOL. 5
Kyaw Z Thein, et. al.Kyaw Z Thein ... Lacey Mcquinn
01 Feb 2022
545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201)
Giovanni Grignani ... Melissa Burgess
Journal for ImmunoTherapy of Cancer | VOL. 9
Giovanni Grignani, et. al.Giovanni Grignani ... Melissa Burgess
01 Nov 2021
268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101)
Dominique Berton-Rigaud ... Nawel Bourayou
Journal for ImmunoTherapy of Cancer | VOL. 8
Dominique Berton-Rigaud, et. al.Dominique Berton-Rigaud ... Nawel Bourayou
01 Nov 2020
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines
Jeffrey Schlom ... James L Gulley
Journal for ImmunoTherapy of Cancer | VOL. 12
Jeffrey Schlom, et. al.Jeffrey Schlom ... James L Gulley
08 Jul 2024
Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinoma
Yang Chen ... Yongsheng Li
Journal for ImmunoTherapy of Cancer | VOL. 12
Yang Chen, et. al.Yang Chen ... Yongsheng Li
08 Jul 2024
Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids
Elias Burri ... Egle Ramelyte
Journal for ImmunoTherapy of Cancer | VOL. 12
Elias Burri, et. al.Elias Burri ... Egle Ramelyte
05 Jul 2024
TCF1-positive and TCF1-negative TRM CD8 T cell subsets and cDC1s orchestrate melanoma protection and immunotherapy response
Saraí G De León-Rodríguez ... Laura C Bonifaz
Journal for ImmunoTherapy of Cancer | VOL. 12
Saraí G De León-Rodríguez, et. al.Saraí G De León-Rodríguez ... Laura C Bonifaz
05 Jul 2024
View more papers